Project 1: Therapeutic Potential of Kappa Opioid Receptor Antagonists in the Treatment of Depression (Chavkin) | Conte Center
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Figure 2 from Development of κ opioid receptor antagonists. | Semantic Scholar
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence - ScienceDirect
Frontiers Publishing Partnerships | Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine
Novel kappa opioid receptor antagonist navacaprant significantly reduces depression symptoms: Phase II study
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy | ACS Chemical Neuroscience
PDF) The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach
Antagonists of the kappa opioid receptor - ScienceDirect
Major Depressive Disorder and Kappa Opioid Receptor
Development of κ Opioid Receptor Antagonists | Journal of Medicinal Chemistry
In major depression, increased kappa and mu opioid receptor levels are associated with immune activation | Acta Neuropsychiatrica | Cambridge Core
Antagonists of the kappa opioid receptor. | Semantic Scholar
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back